K J Busam

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi Analysis of microphthalmia transcription factor expression in normal tissues and tumors, and comparison of its expression with S-100 protein, gp100, and tyrosinase in desmoplastic malignant melanoma
    K J Busam
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Am J Surg Pathol 25:197-204. 2001
  2. ncbi Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions
    Klaus J Busam
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Am J Surg Pathol 37:413-20. 2013
  3. ncbi Combined BRAFV600E-positive Melanocytic Lesions With Large Epithelioid Cells Lacking BAP1 Expression and Conventional Nevomelanocytes
    Klaus J Busam
    Department of Pathology Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center Ludwigs Cancer Research Institute, New York, NY Department of Dermatology, Kaiser Permanente, Walnut Creek, CA Department of Neuropathology, Institute of Pathology, Ruprecht Karls University Heidelberg Clinical Cooperation Unit Neuropathology, German Cancer Research Center DKFZ, Heidelberg, Germany
    Am J Surg Pathol 37:193-9. 2013
  4. ncbi Diagnosis of blue nevus-like metastatic uveal melanoma confirmed by fluorescence in situ hybridization (FISH) for monosomy 3
    Klaus J Busam
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Cutan Pathol 39:621-5. 2012
  5. ncbi Functional polymorphisms in the promoter regions of MMP2 and MMP3 are not associated with melanoma progression
    Javier Cotignola
    Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Negat Results Biomed 6:9. 2007
  6. ncbi Matrix Metalloproteinase-9 (MMP-9) polymorphisms in patients with cutaneous malignant melanoma
    Javier Cotignola
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    BMC Med Genet 8:10. 2007
  7. ncbi Detection of intraepidermal malignant melanoma in vivo by confocal scanning laser microscopy
    K J Busam
    Departments of Pathology, Dermatology Service, Memorial Sloan Kettering Cancer Center, 1275 York Ave, NY 10021, USA
    Melanoma Res 12:349-55. 2002
  8. ncbi Sentinel lymph node biopsy for patients with diagnostically controversial Spitzoid melanocytic tumors?
    Klaus J Busam
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Adv Anat Pathol 15:253-62. 2008
  9. ncbi Atypical spitzoid melanocytic tumors with positive sentinel lymph nodes in children and teenagers, and comparison with histologically unambiguous and lethal melanomas
    Klaus J Busam
    Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Am J Surg Pathol 33:1386-95. 2009
  10. ncbi Merkel cell polyomavirus expression in merkel cell carcinomas and its absence in combined tumors and pulmonary neuroendocrine carcinomas
    Klaus J Busam
    Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Am J Surg Pathol 33:1378-85. 2009

Detail Information

Publications99

  1. ncbi Analysis of microphthalmia transcription factor expression in normal tissues and tumors, and comparison of its expression with S-100 protein, gp100, and tyrosinase in desmoplastic malignant melanoma
    K J Busam
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Am J Surg Pathol 25:197-204. 2001
    ..Especially in re-excisions, when immunohistochemistry is often needed to distinguish an inflamed scar tissue from tumor, the presence of immunopositive inflammatory cells and fibroblasts limits the diagnostic use of D5...
  2. ncbi Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions
    Klaus J Busam
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Am J Surg Pathol 37:413-20. 2013
    ..The high specificity and sensitivity of VE1 for the detection of mutant BRAF(V600E) suggests a valuable reagent for clinical purposes. Heterogeneity in BRAF expression may be relevant for treatment response to BRAF inhibitors...
  3. ncbi Combined BRAFV600E-positive Melanocytic Lesions With Large Epithelioid Cells Lacking BAP1 Expression and Conventional Nevomelanocytes
    Klaus J Busam
    Department of Pathology Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center Ludwigs Cancer Research Institute, New York, NY Department of Dermatology, Kaiser Permanente, Walnut Creek, CA Department of Neuropathology, Institute of Pathology, Ruprecht Karls University Heidelberg Clinical Cooperation Unit Neuropathology, German Cancer Research Center DKFZ, Heidelberg, Germany
    Am J Surg Pathol 37:193-9. 2013
    ..The lesions described herein may represent a peculiar combined melanocytic nevus variant. However, longer follow-up and more studies are needed to determine the biological potential of the BAP1-negative melanocyte proliferations...
  4. ncbi Diagnosis of blue nevus-like metastatic uveal melanoma confirmed by fluorescence in situ hybridization (FISH) for monosomy 3
    Klaus J Busam
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Cutan Pathol 39:621-5. 2012
    ..Furthermore, deletion of 1p36 and amplifications of 8q32 were also identified...
  5. ncbi Functional polymorphisms in the promoter regions of MMP2 and MMP3 are not associated with melanoma progression
    Javier Cotignola
    Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Negat Results Biomed 6:9. 2007
    ..Functional polymorphisms in MMP genes' promoter regions may modulate the risk for melanoma progression...
  6. ncbi Matrix Metalloproteinase-9 (MMP-9) polymorphisms in patients with cutaneous malignant melanoma
    Javier Cotignola
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    BMC Med Genet 8:10. 2007
    ..Some polymorphisms are known to influence gene expression, protein activity, stability, and interactions, and they were shown to be associated with certain tumor phenotypes and cancer risk...
  7. ncbi Detection of intraepidermal malignant melanoma in vivo by confocal scanning laser microscopy
    K J Busam
    Departments of Pathology, Dermatology Service, Memorial Sloan Kettering Cancer Center, 1275 York Ave, NY 10021, USA
    Melanoma Res 12:349-55. 2002
    ..Thus, the application of CSLM represents a new tool for non-invasive screening of intraepidermal pigmented lesions in vivo and offers the opportunity to bring histopathological analysis to the bedside...
  8. ncbi Sentinel lymph node biopsy for patients with diagnostically controversial Spitzoid melanocytic tumors?
    Klaus J Busam
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Adv Anat Pathol 15:253-62. 2008
    ..Although SLN biopsy provides prognostic information helpful for clinical trials, we caution against performing the procedure as a diagnostic adjunct...
  9. ncbi Atypical spitzoid melanocytic tumors with positive sentinel lymph nodes in children and teenagers, and comparison with histologically unambiguous and lethal melanomas
    Klaus J Busam
    Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Am J Surg Pathol 33:1386-95. 2009
    ..Our findings confirm that children and teenagers with ASMTs and positive SLNs have a less aggressive clinical course than those with histologically unambiguous melanoma...
  10. ncbi Merkel cell polyomavirus expression in merkel cell carcinomas and its absence in combined tumors and pulmonary neuroendocrine carcinomas
    Klaus J Busam
    Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Am J Surg Pathol 33:1378-85. 2009
    ..It labels the majority of MCCs, but fails to react with pulmonary neuroendocrine carcinomas. We also found that neuroendocrine carcinomas of the skin arising in association with a squamous cell carcinoma seem to be independent of MCV...
  11. ncbi Congenital pauci-melanotic cellular blue nevus
    Klaus J Busam
    Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Cutan Pathol 31:312-7. 2004
    ..The nevi are presented here to enhance our knowledge of the morphologic spectrum of melanocytic tumors and to help avoid confusion with malignant melanoma...
  12. ncbi Clusterin expression in primary and metastatic melanoma
    Klaus J Busam
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Cutan Pathol 33:619-23. 2006
    ..Our findings confirm the observation that clusterin can be expressed in melanoma, in particular primary desmoplastic melanoma. However, clusterin appears to be present only in a minority of melanomas...
  13. ncbi Malignant melanoma metastatic to a basal cell carcinoma simulating the pattern of a basomelanocytic tumor
    Klaus J Busam
    Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Am J Surg Pathol 30:133-6. 2006
    ..To our knowledge, this is the first description of metastatic melanoma colonizing a BCC...
  14. ncbi Immunohistochemical analysis of novel monoclonal antibody PNL2 and comparison with other melanocyte differentiation markers
    Klaus J Busam
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Am J Surg Pathol 29:400-6. 2005
    ..Despite its reactivity with neutrophils, PNL2 appears to be a valuable supplementary reagent for the diagnosis of melanocytic tumors...
  15. ncbi Eruptive melanotic macules and papules associated with adenocarcinoma
    Klaus J Busam
    Department of Pathology, Clinical Immunology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Cutan Pathol 30:463-9. 2003
    ..Malignancies may be associated with paraneoplastic cutaneous manifestations, including pigmentary disorders...
  16. ncbi Distinction of desmoplastic melanoma from non-desmoplastic melanoma by gene expression profiling
    Klaus J Busam
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Invest Dermatol 124:412-8. 2005
    ..Our results from gene expression profiling validate the distinction of DM from NDM. They also provide the opportunity to learn more about the biology of DM which had previously not yet been associated with this variant of melanoma...
  17. ncbi Cutaneous desmoplastic melanoma: reappraisal of morphologic heterogeneity and prognostic factors
    Klaus J Busam
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Am J Surg Pathol 28:1518-25. 2004
    ..Failure to make this distinction may account for conflicting reports in the literature on the biologic behavior and prognosis of DM...
  18. ncbi The use and application of special techniques in assessing melanocytic tumours
    Klaus J Busam
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Pathology 36:462-9. 2004
    ..Most recently, molecular techniques are being explored for their potential use in the diagnosis of melanoma. In this review, various modalities are discussed with regard to their application in the evaluation of melanocytic neoplasms...
  19. ncbi Diffuse melanosis after chemotherapy-induced tumor lysis syndrome in a patient with metastatic melanoma
    Klaus J Busam
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Cutan Pathol 31:274-80. 2004
    ..These findings document that diffuse melanosis may result from tumor lysis, with release of melanosomes into the bloodstream...
  20. ncbi Distinction of conjunctival melanocytic nevi from melanomas by fluorescence in situ hybridization
    Klaus J Busam
    Department of Pathology, Ophthalmologic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Cutan Pathol 37:196-203. 2010
    ..The findings encourage further exploration of this technique as an ancillary method for the work-up of conjunctival melanocytic proliferations...
  21. ncbi Epidermal growth factor, estrogen, and progesterone receptor expression in primary sweat gland carcinomas and primary and metastatic mammary carcinomas
    K J Busam
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Mod Pathol 12:786-93. 1999
    ..001). The frequencies of expression of ER and PR in SGCs and BCs metastatic to skin were not significantly different...
  22. ncbi Morphologic features of melanocytes, pigmented keratinocytes, and melanophages by in vivo confocal scanning laser microscopy
    K J Busam
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Mod Pathol 14:862-8. 2001
    ..This technique sets a new paradigm for noninvasive quasihistologic examination of pigmented lesions in vivo and merits further evaluation for diagnostic use...
  23. ncbi Detection of clinically amelanotic malignant melanoma and assessment of its margins by in vivo confocal scanning laser microscopy
    K J Busam
    Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    Arch Dermatol 137:923-9. 2001
    ..Near-infrared confocal scanning laser microscopy (CSLM) represents a novel imaging technique for in vivo microscopic analysis of skin lesions, including pigmented lesions...
  24. ncbi Desmoplastic melanoma
    Klaus J Busam
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Lab Med 31:321-30. 2011
    ..DM differs from conventional melanoma in its clinical course. It is associated with a higher tendency for local recurrence, but metastases to regional lymph nodes are less common...
  25. ncbi Xanthogranulomas with inconspicuous foam cells and giant cells mimicking malignant melanoma: a clinical, histologic, and immunohistochemical study of three cases
    K J Busam
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Am J Surg Pathol 24:864-9. 2000
    ..Their occurrence in adolescents and adults is underrecognized. Knowledge of this variant is important to avoid misdiagnosing a benign tumor as malignant melanoma...
  26. ncbi Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225
    K J Busam
    Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Br J Dermatol 144:1169-76. 2001
    ..Conclusions Our findings support the concept that p27Kip1 plays a part in the in vivo regulation of follicular and epidermal homeostasis by EGFR...
  27. ncbi Immunoreactivity with the anti-MAGE antibody 57B in malignant melanoma: frequency of expression and correlation with prognostic parameters
    K J Busam
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Mod Pathol 13:459-65. 2000
    ..Furthermore, the seeming restriction of immunopositivity to invasive malignant tumors suggests a potential diagnostic role for the antibody 57B in confirming the malignant potential of a melanocytic tumor...
  28. ncbi Cutaneous desmoplastic melanoma
    Klaus J Busam
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Adv Anat Pathol 12:92-102. 2005
    ..Evidence is also emerging that for patients with thick melanomas, the presence of a paucicellular fibrosing tumor histology (pure DM) is a favorable prognostic factor for survival...
  29. ncbi Expression of melanocyte-associated markers gp-100 and Melan-A/MART-1 in angiomyolipomas. An immunohistochemical and rt-PCR analysis
    A A Jungbluth
    Ludwig Institute for Cancer Research at Memorial Sloan Kettering Cancer Center, New York 10021, USA
    Virchows Arch 434:429-35. 1999
    ..Our study demonstrates that A103 is a useful marker for the diagnosis of angiomyolipomas...
  30. ncbi Monoclonal antibody MA454 reveals a heterogeneous expression pattern of MAGE-1 antigen in formalin-fixed paraffin embedded lung tumours
    A A Jungbluth
    Ludwig Institute for Cancer Research at Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Br J Cancer 83:493-7. 2000
    ..The predominantly focal expression of MAGE-1 suggests that this antigen might not be sufficient as a sole target for immunotherapeutic approaches...
  31. ncbi Immunohistochemical and reverse transcription-polymerase chain reaction expression analysis of tyrosinase and microphthalmia-associated transcription factor in angiomyolipomas
    A A Jungbluth
    Ludwig Institute for Cancer Research at Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Appl Immunohistochem Mol Morphol 9:29-34. 2001
    ..The current results show that in contrast with HMB45 and A103, T311 has little or no value in the diagnosis of AMLs. D5 may be useful in a panel of antibodies in the diagnosis of AMLs...
  32. ncbi A103: An anti-melan-a monoclonal antibody for the detection of malignant melanoma in paraffin-embedded tissues
    A A Jungbluth
    Ludwig Institute for Cancer Research, New York Branch, Memorial Sloan Kettering Cancer Center, New York 10021, USA
    Am J Surg Pathol 22:595-602. 1998
    ..This A103 immunoreactivity in benign and neoplastic tissues of nonmelanocytic origin, the basis of which is unclear, could also be of potential diagnostic value...
  33. ncbi Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues
    A A Jungbluth
    Ludwig Institute for Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Int J Cancer 92:856-60. 2001
    ..There is great variability in NY-ESO-1 expression in individual tumors, ranging from an infrequent homogeneous pattern of staining to highly heterogeneous antigen expression...
  34. ncbi Expression of melanocytic differentiation markers in malignant melanomas of the oral and sinonasal mucosa
    M L Prasad
    Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
    Am J Surg Pathol 25:782-7. 2001
    ..For desmoplastic mucosal tumors, anti-S-100 protein remains the most sensitive marker...
  35. ncbi Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen NY-ESO-1 but not MAGE-A1 or CT7
    A A Jungbluth
    Ludwig Institute for Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Int J Cancer 94:252-6. 2001
    ..Our study shows that NY-ESO-1 is highly expressed in a homogeneous pattern in synovial sarcomas of both morphologic variants and both translocation types, making these tumors an attractive target for NY-ESO-1 antigen-based immunotherapy...
  36. ncbi Expression of MAGE-antigens in normal tissues and cancer
    A A Jungbluth
    Ludwig Institute for Cancer Research, New York, NY 10021, USA
    Int J Cancer 85:460-5. 2000
    ..Tumor specimens showed great variability in the number of tumor cells showing 57B reactivity, with some tumors showing only small isolated clusters of positive cells to other tumors with uniform staining throughout the tumor...
  37. ncbi Primary cutaneous melanoma with regression does not require a lower threshold for sentinel lymph node biopsy
    Katherine T Morris
    Gastric and Mixed Tumor Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA
    Ann Surg Oncol 15:316-22. 2008
    ..Histological evidence of primary tumor regression (RG) is observed in 35% or fewer patients with cutaneous melanoma. Some advocate a lower threshold for sentinel lymph node (SLN) biopsy when RG is present...
  38. ncbi Subungual melanoma: management considerations
    Tzeela Cohen
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Am J Surg 195:244-8. 2008
    ..Patients with subungual melanoma (SM) often experience delayed diagnosis and present with deep primary lesions. Breslow depth of the primary lesion is often unknown before definitive resection, thus complicating treatment planning...
  39. ncbi Histologic classification of tumor-infiltrating lymphocytes in primary cutaneous malignant melanoma. A study of interobserver agreement
    K J Busam
    Dept of Pathology, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    Am J Clin Pathol 115:856-60. 2001
    ..75). These findings suggest that the categorization of TILs can be easily taught and can be applied with an acceptable level of reproducibility in routine diagnostic practice...
  40. ncbi Prognostic implications of multiple lymphatic basin drainage in patients with truncal melanoma
    Ramon E Jimenez
    Gastric and Mixed Tumor Service, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 23:518-24. 2005
    ..7; P = .03). CONCLUSION: MLBD in patients with truncal melanoma undergoing SLN mapping is associated with a less favorable survival compared with patients with SLBD, independent of SLN status...
  41. ncbi Expression of melanocyte differentiation antigens and ki-67 in nodal nevi and comparison of ki-67 expression with metastatic melanoma
    Christina M Lohmann
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Am J Surg Pathol 26:1351-7. 2002
    ..Immunohistochemistry for S-100 protein, Melan-A/MART-1, or tyrosinase facilitates the recognition of melanocytes but does not distinguish between nodal nevus and metastatic melanoma...
  42. ncbi Results of sentinel lymph node biopsy in patients with thin melanoma
    Sandra L Wong
    Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA
    Ann Surg Oncol 13:302-9. 2006
    ..75 mm and Clark level II or III melanoma. In our experience, no single clinicopathologic factor was predictive of nodal metastases. The prognostic implications of positive SLNs in thin melanoma remain undefined...
  43. ncbi Microscopic satellitosis in patients with primary cutaneous melanoma: implications for nodal basin staging
    Troy F Kimsey
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Ann Surg Oncol 16:1176-83. 2009
    ..Microscopic satellitosis in melanoma is uncommon. The role of regional basin staging/therapy in patients with this high-risk feature has not been well defined...
  44. ncbi Clinical application of dynamic telepathology in Mohs surgery
    Sean A Sukal
    Department of Dermatology, New York Presbyterian Weill Cornell Medical Center, New York, NY 10022, USA
    Dermatol Surg 31:1700-3. 2005
    ..CONCLUSION: Dynamic telepathology is a useful and convenient adjunct in the Mohs surgery practice for intraoperative consultations on difficult frozen sections...
  45. ncbi Merkel cell carcinoma: histologic features and prognosis
    Aleodor A Andea
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer 113:2549-58. 2008
    ..Currently, little is known regarding the potential prognostic value of histologic features in primary cutaneous neuroendocrine (Merkel cell) carcinomas (MCC)...
  46. ncbi Expression and significance of cancer testis antigens in primary mucosal melanoma of the head and neck
    Manju L Prasad
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Head Neck 26:1053-7. 2004
    ..Primary mucosal melanomas of the head and neck (HNMM) are rare aggressive malignant tumors that are usually difficult to treat. CTAs may provide useful targets for therapy; however, their expression in HNMM is not known...
  47. ncbi Reflectance confocal microscopy of pigmented basal cell carcinoma
    Anna Liza Chan Agero
    Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10022, USA
    J Am Acad Dermatol 54:638-43. 2006
    ..CONCLUSION: RCM may permit in vivo diagnosis of pigmented BCC...
  48. ncbi Cutaneous metastatic breast carcinoma with melanocyte colonization: a clinical and dermoscopic mimic of malignant melanoma
    Angela J Wyatt
    Department of Dermatology, New York Presbyterian Hospital, Weill Medical College of Cornell University, New York, New York 10022, USA
    Dermatol Surg 32:949-54. 2006
    ....
  49. ncbi Melanoma or pigmented basal cell carcinoma: a clinical-pathologic correlation with dermoscopy, in vivo confocal scanning laser microscopy, and routine histology
    Carlos A Charles
    Dermatology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Skin Res Technol 8:282-7. 2002
    ..Conventional histology confirmed the diagnosis of pigmented BCC. CONCLUSION: Confocal scanning laser microscopy (CSLM) may serve as an aid in the non-invasive diagnosis of pigmented skin lesions clinically suspicious for melanoma...
  50. ncbi L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition
    Cristina R Antonescu
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Int J Cancer 121:257-64. 2007
    ..These results suggest that a subset of anal melanomas show activating KIT mutations, which are susceptible for therapy with specific kinase inhibitors...
  51. ncbi CT7 (MAGE-C1) antigen expression in normal and neoplastic tissues
    Achim A Jungbluth
    Ludwig Institute for Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Int J Cancer 99:839-45. 2002
    ....
  52. ncbi Ex vivo dermoscopy of melanocytic tumors: time for dermatopathologists to learn dermoscopy
    Alon Scope
    Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 160 E 53rd St, New York, NY 10022, USA
    Arch Dermatol 143:1548-52. 2007
    ..Noncontact polarized dermoscopy was applied to pigmented lesions before excision and at least 6 hours after specimen fixation in formalin...
  53. ncbi Use of dynamic telepathology in Mohs surgery: a feasibility study
    Kishwer S Nehal
    Dermatology Service and Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Dermatol Surg 28:422-6. 2002
    ..Telepathology is an emerging technology for remote pathology consultation and diagnosis...
  54. ncbi In vivo reflectance confocal microscopy imaging of melanocytic skin lesions: consensus terminology glossary and illustrative images
    Alon Scope
    Dermatology Service, Memorial Sloan Kettering Cancer Center, New York, New York 10022, USA
    J Am Acad Dermatol 57:644-58. 2007
    ..Reflectance confocal microscopy (RCM) has been used for over 10 years for in vivo skin imaging. However, to date no standard RCM terminology has been published...
  55. ncbi Outcome of patients with a positive sentinel lymph node who do not undergo completion lymphadenectomy
    T Peter Kingham
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Ann Surg Oncol 17:514-20. 2010
    ..This study evaluates the outcome of patients who had a positive SLN but did not undergo CLND at Memorial Sloan-Kettering Cancer Center...
  56. ncbi Value of frozen-section analysis of sentinel lymph nodes for primary cutaneous malignant melanoma
    Alexander Stojadinovic
    Departments of Surgery and Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
    Ann Surg 235:92-8. 2002
    ..7%. The false-negative rate for SLN biopsy was 7.5%. CONCLUSIONS: Because the prevalence of metastases within the SLN and sensitivity of FS analysis are low, routine use of FS for all patients undergoing SLN biopsy is not recommended...
  57. ncbi CK7 expression in primary cutaneous squamous cell carcinoma
    Melissa Pulitzer
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Cutan Pathol 37:966-72. 2010
    ..To evaluate cytokeratin 7 (CK7) immunoreactivity in invasive primary cutaneous squamous cell carcinomas (SCCs)...
  58. ncbi Treatment of dysplastic nevi with 5% imiquimod cream, a pilot study
    Stephen W Dusza
    Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10022, USA
    J Drugs Dermatol 5:56-62. 2006
    ....
  59. ncbi Sentinel lymph node analysis in patients with sweat gland carcinoma
    Ruby Delgado
    Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
    Cancer 97:2279-84. 2003
    ..As in SLNBs of other tumors, immunohistochemistry appears to facilitate the recognition of small microscopic metastases...
  60. ncbi In vivo confocal scanning laser microscopy of a series of congenital melanocytic nevi suggestive of having developed malignant melanoma
    Ashfaq A Marghoob
    Dermatology Service, Memorial Sloan Kettering Cancer Center, New York, NY 11788, USA
    Arch Dermatol 141:1401-12. 2005
    ..To determine the utility of confocal scanning laser microscopy (CSLM) in the in vivo evaluation of congenital melanocytic nevi (CMNs) that are suggestive of having developed melanoma...
  61. ncbi Sentinel lymph node biopsy in patients with diagnostically controversial spitzoid melanocytic tumors
    Christina M Lohmann
    Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
    Am J Surg Pathol 26:47-55. 2002
    ....
  62. ncbi Primary malignant melanoma of the oesophagus: a clinical and pathological study with emphasis on the immunophenotype of the tumours for melanocyte differentiation markers and cancer/testis antigens
    Christina M Lohmann
    Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York 10021, USA
    Melanoma Res 13:595-601. 2003
    ..In addition, they were all positive for CT antigens, with MA454 being the most commonly found, suggesting that CT antigens may be a promising immunotherapeutic target for oesophageal melanomas...
  63. ncbi Multiple subclinical syringomatous proliferations encountered during Mohs surgery for basal cell carcinoma
    Snehal P Amin
    Department of Dermatology, Presbyterian Hospital of Cornell University, New York, New York 10022, USA
    Dermatol Surg 30:1420-3; discussion 1423. 2004
    ..Dermatologists should be aware of the existence of this phenomenon and consider permanent section evaluation to better determine nature of unusual incidental tumors identified in frozen sections during Mohs surgery...
  64. ncbi Treatment of primary miliary osteoma cutis with incision, curettage, and primary closure
    J F Altman
    Dermatology Service, Memorial Sloan Kettering Cancer Center, NewYork, NY, USA
    J Am Acad Dermatol 44:96-9. 2001
    ..CONCLUSION: This surgical technique offers a simple but effective method for removal of multiple bony fragments in primary miliary osteoma cutis with minimal side effects...
  65. ncbi Lack of relevant information for tumor staging in pathology reports of primary cutaneous melanoma
    K J Busam
    Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
    Am J Clin Pathol 115:743-6. 2001
    ..Therefore, review of outside pathology material is necessary not only to confirm or revise the tumor diagnosis but also to provide clinicians with histologic parameters required for AJCC staging...
  66. ncbi Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma
    Rebecca C Taylor
    Departments of Surgery, Biostatistics, and Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 25:869-75. 2007
    ..The prognostic implications of TILs were re-evaluated in a large group of patients undergoing SLN biopsy at our institution...
  67. ncbi Merkel cell carcinoma: review
    Melissa P Pulitzer
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Adv Anat Pathol 16:135-44. 2009
    ..Surgical excision is the treatment of choice, but radiation therapy has also found to be effective. Sentinel lymph node biopsy has become an integral part of the staging of patients with MCC...
  68. ncbi Yield and predictors of radiologic studies for identifying distant metastases in melanoma patients with a positive sentinel lymph node biopsy
    Jason S Gold
    Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Ann Surg Oncol 14:2133-40. 2007
    ..It is common to obtain radiological studies around the time of a positive sentinel lymph node biopsy (SLNB) to exclude patients with distant metastases from completion lymph node dissection. The yield of such a work-up is unknown...
  69. ncbi Histologic distinction between subungual lentigo and melanoma
    Bijal Amin
    Department of Pathology, The New York Presbyterian, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Am J Surg Pathol 32:835-43. 2008
    ....
  70. ncbi Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation
    Gudrun Ratzinger
    Laboratory of Cellular Immunobiology, Department of Medicine, Weill Medical College of Cornell University, New York, NY, USA
    Blood 101:1422-9. 2003
    ..Whether these results support a separation of deleterious from beneficial graft-host interactions at the level of antigen presentation, rather than solely at the level of T cells, will require further evaluation...
  71. ncbi Melanonychia following mohs surgery for recurrent squamous cell carcinoma in situ of the nail bed
    Jules B Lipoff
    Dermatology Service and Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Cutan Med Surg 12:194-7. 2008
    ..Melanonychia can occur from many causes, including racial predisposition, trauma, drugs, pregnancy, Addison disease, Peutz-Jeghers syndrome, Laugier-Hunziker syndrome, Bowen disease, onychomycosis, benign nail matrix nevi, and melanoma...
  72. ncbi Agminated atypical (dysplastic) nevi: case report and review of the literature
    A A Marghoob
    Dermatology Service, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    Arch Dermatol 137:917-20. 2001
    ..The presence of agminated atypical (dysplastic) nevi in a patient with the atypical mole syndrome can be theorized to arise because of loss of heterozygosity...
  73. ncbi Tumor necrosis factor-alpha and interleukin-1 antagonists alleviate inflammatory skin changes associated with epidermal growth factor receptor antibody therapy in mice
    David Surguladze
    Research Division, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, New York, New York 10014, USA
    Cancer Res 69:5643-7. 2009
    ..Our results provide a mechanistic framework to develop evidence-based trials for EGFR antibody-induced skin rash in patients with cancer...
  74. ncbi MAGE antigen expression in monophasic and biphasic synovial sarcoma
    Cristina R Antonescu
    Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
    Hum Pathol 33:225-9. 2002
    ..Our study demonstrates that MAGE is frequently and homogeneously expressed in synovial sarcomas of both morphological variants and both translocation types, making these tumors an attractive target for MAGE antigen-based immunotherapy...
  75. ncbi Primary mucosal desmoplastic melanoma of the head and neck
    Manju L Prasad
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Head Neck 26:373-7. 2004
    ..Desmoplastic variants of melanoma rarely affect the mucosa...
  76. ncbi Evaluation of the clonal origin of multiple primary melanomas using molecular profiling
    Irene Orlow
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Invest Dermatol 129:1972-82. 2009
    ....
  77. ncbi Primary mucosal melanoma of the head and neck: a proposal for microstaging localized, Stage I (lymph node-negative) tumors
    Manju L Prasad
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer 100:1657-64. 2004
    ..The current study was conducted to identify histologic predictors of survival in patients with localized, lymph node-negative (Stage I, N0M0) primary mucosal melanomas of the head and neck (HNMM)...
  78. ncbi Staged excision for lentigo maligna and lentigo maligna melanoma: A retrospective analysis of 117 cases
    Carole Hazan
    Department of Dermatology, Memorial Sloan Kettering Cancer Center, New York, New York 10022, USA
    J Am Acad Dermatol 58:142-8. 2008
    ..Complete surgical excision for lentigo maligna (LM) and LM melanoma (LMM) in the head and neck region may be challenging because of potential significant subclinical extension...
  79. ncbi Are all melanomas the same? Spitzoid melanoma is a distinct subtype of melanoma
    David A Lee
    Department of Dermatology, Columbia University Medical Center, New York, NY 10032, USA
    Cancer 106:907-13. 2006
    ..In this study, the authors evaluated the contribution of B-RAF and N-RAS mutations to the pathogenesis of Spitzoid melanomas...
  80. ncbi Prognostic factors for malignant melanoma of the squamous mucosa of the head and neck
    Manju L Prasad
    Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
    Am J Surg Pathol 26:883-92. 2002
    ..Thus, the histologic parameters relevant for the prognosis of squamous mucosa differ significantly from those of cutaneous melanomas...
  81. ncbi The role of abdominoperineal resection as surgical therapy for anorectal melanoma
    Jen Jen Yeh
    Memorial-Sloan Kettering Cancer Center, New York, NY 10021, USA
    Ann Surg 244:1012-7. 2006
    ..Therefore, LE of the primary tumor is recommended when technically feasible. The presence of PNI is an important prognostic factor and should be considered in future clinical trials...
  82. ncbi Dispelling the myth of the "benign hair sign" for melanoma
    Alon Scope
    Departments of Dermatology, Memorial Sloan Kettering Cancer Center, New York 10022, USA
    J Am Acad Dermatol 56:413-6. 2007
    ..Thus, integrating all clinical and dermoscopic findings, rather than relying on a single criterion for the lesion at hand should guide clinicians to the correct diagnosis...
  83. ncbi Cutaneous melanoma arising in a burn scar: two recent cases and a review of the literature
    Suzannah M Bero
    Memorial Sloan-Kettering Cancer Center, New York 10021, USA
    Melanoma Res 16:71-6. 2006
    ..Only 27 patients have been reported previously, and only three previous cases of multiple primary melanomas arising in a burn scar have been described...
  84. ncbi Primary cutaneous peripheral T-cell lymphoma with aberrant coexpression of CD20: case report and review of the literature
    Nicole N Balmer
    Department of Pathology, University of Alabama at Birmingham, Birmingham, AL, USA
    Am J Dermatopathol 31:187-92. 2009
    ..In conclusion, we present a case a of CD8-positive primary cutaneous T-cell lymphoma with CD20 expression, exhibiting aggressive behavior...
  85. ncbi Surgical management of melanoma of the gallbladder: a report of 13 cases and review of the literature
    Steven C Katz
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Am J Surg 193:493-7. 2007
    ..Melanoma has the potential to spread to virtually any organ, including the gallbladder. The role of intervention in this rare entity must be based on a thorough appreciation of the underlying disease biology...
  86. ncbi Multiple infundibulocystic basal cell carcinomas: case report of unique unilateral presentation
    Alysa R Herman
    Department of Dermatology, Presbyterian Hospital of Cornell University, New York, USA
    Dermatol Surg 29:436-9. 2003
    ..A management approach with clinical follow-up and surgical intervention only for changing lesions is discussed...
  87. ncbi Distinct sets of genetic alterations in melanoma
    John A Curtin
    Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94143-0808, USA
    N Engl J Med 353:2135-47. 2005
    ....
  88. ncbi Prediction of nonsentinel lymph node status in melanoma
    Mark E Reeves
    Department of Surgery, Loma Linda University and VA Medical Centers, Loma Linda, California, USA
    Ann Surg Oncol 10:27-31. 2003
    ..No patient with an SU score of 0 had a positive NSLN. CONCLUSIONS: The SU score is predictive of NSLN status in patients with a positive SLND. Patients with an SU score of 0 are very unlikely to have positive NSLNs at CLND...
  89. ncbi Desmoplastic melanoma: a pathologically and clinically distinct form of cutaneous melanoma
    William G Hawkins
    Department of Surgery, Washington University, St. Louis, Missouri 63110, USA
    Ann Surg Oncol 12:207-13. 2005
    ..Tumors with prominent fibrosis (pure subtype) are unlikely to disseminate to regional lymph nodes and are associated with a favorable outcome when compared with those with mixed desmoplasia or CM...
  90. ncbi The prognostic importance of tumor mitotic rate for patients with primary cutaneous melanoma
    Klaus J Busam
    Ann Surg Oncol 11:360-1. 2004
  91. ncbi NY-BR-1 is a differentiation antigen of the mammary gland
    Dirk Jager
    Medizinische Onkologie NCT, University Hospital Heidelberg, 69120 Heidelberg, Germany
    Appl Immunohistochem Mol Morphol 15:77-83. 2007
    ..These data indicate that NY-BR-1 is a differentiation antigen of the mammary gland that could be useful for diagnosis and/or immunotherapy of breast carcinomas...
  92. ncbi Histologically benign cutaneous dendritic cell tumor with pseudorosettes
    James M Woodruff
    Am J Surg Pathol 26:1644-5; author reply 1645-8. 2002
  93. ncbi Genomic analysis of blue nevi and related dermal melanocytic proliferations
    John C Maize
    Department of Dermatology, Medical University of South Carolina, Charleston, SC, USA
    Am J Surg Pathol 29:1214-20. 2005
    ..Ambiguous lesions can be separated into lesions with and without chromosomal aberrations. Future studies with clinical follow-up are necessary to determine which aberrations are most informative for classification of these lesions...
  94. ncbi Sentinel lymph node biopsy for patients with melanoma--introductory comments
    Klaus J Busam
    Semin Diagn Pathol 25:83-5. 2008
  95. ncbi Advances in molecular staging of melanoma patients: multimarker analysis of archival lymph node tissue
    Klaus J Busam
    J Clin Oncol 21:3550-1. 2003
  96. ncbi Dermatologic side effects associated with the epidermal growth factor receptor inhibitors
    Anna Liza C Agero
    Dermatology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
    J Am Acad Dermatol 55:657-70. 2006
    ..Secondary adverse reactions seen with anti-EGFR therapy include xerosis, pruritus, paronychia, hair abnormality, and mucositis...
  97. ncbi Clinicopathologic differences in malignant melanoma arising in oral squamous and sinonasal respiratory mucosa of the upper aerodigestive tract
    Manju L Prasad
    Department of Pathology, Ohio State University Medical Center, Columbus 43210
    Arch Pathol Lab Med 127:997-1002. 2003
    ....
  98. ncbi Bluish papule in a middle-aged man
    Rachel P Dubroff
    Columbia University Medical Center and Memorial Sloan-Kettering Cancer Center, New York, NY
    Arch Dermatol 141:1595-600. 2005
  99. ncbi Melanoma diagnosis by confocal microscopy: promise and pitfalls
    Klaus J Busam
    J Invest Dermatol 125:vii. 2005